# EDIT — slm-full-gpu

## Metadata

ticker: EDIT
arm: slm-full-gpu
judge_prompt_version: v2
context_sha256: f3d053e6d9b007788c32c90c5fb6090f0e19ea8e134c2e74d892b4e6cd68eb99
slm_endpoint: slm-gpu
slm_url: http://132.145.161.150:30880
slm_served_name: qwen3.6-35b-a3b-q4km
slm_artifact: ggml-org/Qwen3.6-35B-A3B-GGUF@baec3ebee244827cda0f4557eafa8b28f7545fa6:Qwen3.6-35B-A3B-Q4_K_M.gguf sha256:671e47e0ec53c665d048b98c3ecbfd5236b5ca9c3e02ed19fc8f81f7b85140c7
slm_build: b11347-5fc4f3c8c
slm_model_path: /models/Qwen3.6-35B-A3B-Q4_K_M.gguf
slm_model_ftype: Q4_K - Medium
slm_total_slots: 4
slm_n_ctx: 32768
slm_n_params: 34660610688
slm_model_size_bytes: 20408576512
slm_thinking: off
slm_sampling: {"planner": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "rag": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 2048, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "react": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 1024, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.0, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "section": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 768, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.1, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}, "synthesis": {"chat_template_kwargs": {"enable_thinking": false}, "dry_multiplier": 0.0, "frequency_penalty": 0.0, "max_tokens": 4096, "min_p": 0.0, "presence_penalty": 0.0, "repeat_penalty": 1.0, "temperature": 0.2, "top_k": 20, "top_n_sigma": -1.0, "top_p": 0.8, "typical_p": 1.0, "xtc_probability": 0.0}}
llm_calls: 7
llm_endpoints: slm-gpu
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 682, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 10.863, "latency_s_total": 10.863, "parse_failure": 0, "prompt_tokens": 2385, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 526, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 9.34, "latency_s_total": 9.34, "parse_failure": 0, "prompt_tokens": 2374, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 123, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.483, "latency_s_total": 4.483, "parse_failure": 0, "prompt_tokens": 645, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 194, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.555, "latency_s_total": 5.555, "parse_failure": 0, "prompt_tokens": 639, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 200, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.624, "latency_s_total": 5.624, "parse_failure": 0, "prompt_tokens": 598, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 164, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.14, "latency_s_total": 5.14, "parse_failure": 0, "prompt_tokens": 762, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1025, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 11.299, "latency_s_total": 11.299, "parse_failure": 0, "prompt_tokens": 1740, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.62,
  "currency": "USD",
  "market_cap": 402379680.0,
  "forward_pe": -3.4788148,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "dividend_yield": 0.0,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] Based on the provided text from the SEC EDGAR filings for ticker EDIT, here are the key takeaways regarding the company's financial position, operational status, and risks:

**Financial Position and Capital Needs**
*   **Significant Losses:** The company has incurred substantial operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit stood at $1.6 billion.
*   **Need for Additional Funding:** The company requires substantial additional capital to fund ongoing operations. Existing cash and cash equivalents are expected to fund operating expenses and capital expenditures only through the third quarter of 2027.
*   **Limited External Sources:** As of December 31, 2025, the company’s only significant committed potential external sources of funds are rights to contingent payments under collaboration agreements with BMS and retained portions of payments under a license agreement with Vertex.
*   **Risks of Capital Raising:** If the company cannot raise capital when needed or on attractive terms, it may be forced to delay, reduce, or eliminate research, product development, or commercialization efforts. Raising additional capital may also cause dilution to stockholders or require the relinquishment of rights to technologies.

**Operational Status and Development**
*   **Preclinical Stage:** The company’s most advanced research programs are currently in the preclinical testing stages. It is expected to be many years, if ever, before a product candidate is ready for commercialization.
*   **Primary Candidate (EDIT-401):** A significant portion of future expenses will be directed toward supporting preclinical studies, preparing for clinical development, and initiating clinical trials for EDIT-401.
*   **Future Expenses:** Expenses are expected to increase substantially as the company continues research programs, seeks marketing approvals, establishes manufacturing and distribution infrastructure, and hires additional personnel.

**Profitability and Commercialization Risks**
*   **Uncertain Path to Profitability:** The company expects to incur losses for the foreseeable future and may never achieve or maintain profitability. Even if profitability is achieved, it may not be sustainable on a quarterly or annual basis.
*   **Commercialization Challenges:** Generating revenue will depend on successfully identifying product candidates, completing clinical trials, obtaining regulatory approval, and commercializing the medicines. The company does not expect to have commercially available medicines for years, if at all.
*   **Regulatory and Economic Risks:** Expenses could exceed expectations if regulatory authorities (such as the FDA or EMA) require additional studies. Additionally, unfavorable national or global economic conditions, political unrest, or financial market volatility could adversely affect the business by weakening demand, straining suppliers, or limiting the ability to raise capital.

**Funding History**
*   The company has historically financed its operations through public offerings of common stock, collaborations with BMS (via Juno Therapeutics, Inc.), payments from a terminated alliance with Allergan, payments from DRI Healthcare Acquisitions LP, and payments under a license agreement with Vertex Pharmaceuticals.

RAG — RISK FACTORS:
[From Pinecone cache] The primary risk factors disclosed include:

*   **Financial Position and Need for Additional Capital:** The company has incurred significant operating losses since inception, with net losses of $160.1 million, $237.1 million, and $153.2 million for the years ended December 31, 2025, 2024, and 2023, respectively. As of December 31, 2025, the accumulated deficit was $1.6 billion. The company expects to continue incurring significant expenses and operating losses for the foreseeable future and may never achieve profitability.
*   **Need for Substantial Funding:** The company requires substantial additional funding to support ongoing activities, including the preclinical and clinical development of product candidates like EDIT-401, as well as potential commercialization expenses. If capital cannot be raised when needed, the company may be forced to delay, reduce, or eliminate research and development programs or commercialization efforts.
*   **Limited Committed External Funds:** As of December 31, 2025, the company’s existing cash and cash equivalents are expected to fund operations into the third quarter of 2027. The only significant committed potential external sources of funds are rights to contingent payments under collaboration agreements with Bristol Myers Squibb Company (BMS) and retained portions of payments under a license agreement with Vertex Pharmaceuticals.
*   **Regulatory and Development Risks:** The company is currently in the preclinical testing stages for its most advanced research programs. Expenses could increase beyond expectations if regulatory authorities require additional clinical studies. Identifying and developing product candidates is time-consuming, expensive, and uncertain, and the company may never generate the necessary data to obtain marketing approval.
*   **Economic and Political Conditions:** Unfavorable national or global economic conditions, political unrest, or financial crises could adversely affect the business by weakening demand, disrupting supply chains, or making it difficult to raise capital on acceptable terms.
*   **Commercialization Risks:** Even if products receive marketing approval, the company may not become profitable or sustain profitability. Commercial revenues are not expected for years, if ever, and the company may need to establish its own sales, marketing, and distribution infrastructure, incurring significant expenses.
*   **Dilution and Operational Restrictions:** Raising additional capital through equity offerings, debt financings, or other arrangements may cause dilution to stockholders, restrict operations, or require the company to relinquish rights to its technologies or product candidates.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine, Inc. (EDIT) currently trades at $2.62 with a market capitalization of approximately $402.4 million. The company reported revenue of $47.0 million but faces significant profitability challenges, evidenced by a net loss of $73.9 million and a negative profit margin of -157.3%. Consequently, the forward P/E ratio is negative, reflecting ongoing operational losses rather than earnings generation. This financial profile indicates a high-risk investment profile typical of early-stage biotechnology firms reliant on future pipeline developments for value realization.

### Recent Developments

Editas Medicine, Inc. (EDIT) is currently trading at $2.62, reflecting a market capitalization of approximately $402.4 million amid persistent profitability challenges with a net loss of $73.9 million. The company’s most recent 10-K filing on March 9, 2026, highlighted significant risks related to its financial position and the ongoing need for additional capital to sustain operations. With a negative forward P/E ratio and a profit margin of -157%, investors face substantial uncertainty regarding the firm's path to commercial viability. While the stock has recovered slightly from its 52-week low of $1.66, it remains well below its 52-week high of $4.54, indicating continued market skepticism. Consequently, the primary focus for investors remains on the company's ability to secure sufficient funding and demonstrate progress in its gene-editing pipeline.

### SEC Filing Highlights
Editas Medicine reported net losses of $160.1 million in 2025, bringing its accumulated deficit to $1.6 billion as it remains in the preclinical stage with no commercially available products. Management estimates that existing cash reserves will only sustain operations through the third quarter of 2027, necessitating substantial additional capital to fund ongoing research and development. The company’s primary near-term funding sources are limited to contingent payments from its collaboration with BMS and retained payments from Vertex. Failure to secure necessary financing could force the company to delay or eliminate its development programs, particularly for its lead candidate EDIT-401. Consequently, investors face significant risks regarding the company’s ability to achieve profitability or continue operations without dilutive equity raises or strategic partnerships.

### Risk Factors

*   **Substantial Capital Requirements and Liquidity Risk:** The company has incurred significant operating losses and holds a large accumulated deficit, with existing cash expected to fund operations only through Q3 2027. Failure to secure additional funding could force the delay or termination of development programs, while raising capital may result in significant shareholder dilution or operational restrictions.
*   **High Uncertainty in Clinical Development and Regulatory Approval:** As most product candidates remain in preclinical stages, there is no guarantee of successful clinical trials or regulatory approval. Development is time-consuming and expensive, and the company may never generate the necessary data to obtain marketing authorization or achieve profitability.
*   **Dependence on Limited External Funding Sources:** The company relies heavily on contingent payments from collaboration agreements with Bristol Myers Squibb and Vertex Pharmaceuticals for future capital. Unfavorable economic conditions or political instability could disrupt supply chains, weaken demand, or make it difficult to raise capital on acceptable terms.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a preclinical-stage gene-editing company with a market capitalization of approximately $402.4 million, currently navigating significant profitability challenges marked by a net loss of $73.9 million and a negative profit margin of -157.3%. The stock is notable for its precarious liquidity position, as existing cash reserves are projected to sustain operations only through the third quarter of 2027, creating immediate pressure for capital raises or strategic partnerships. The single most important near-term variable shaping the investment outcome is the company’s ability to secure sufficient additional funding to avoid delaying or eliminating its development programs, particularly for lead candidate EDIT-401.

### Outlook
The directional outlook for Editas Medicine is cautiously cautious, driven by the acute tension between its innovative gene-editing platform and its severe liquidity constraints. The primary headwind is the imminent need for capital before Q3 2027, which introduces substantial dilution risk and potential operational curtailment if external funding from BMS or Vertex collaborations does not materialize as expected. Tailwinds exist in the broader market interest in CRISPR-based therapies, but these are currently overshadowed by binary execution risks regarding clinical progression and financing. Investors should closely monitor the company’s cash burn rate, the status of its partnership payments, and any announcements regarding equity raises or strategic alliances; a successful financing event or positive clinical data readout would strengthen the thesis, whereas delays in funding or development milestones would significantly weaken the investment case.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the **Executive Summary** and **Outlook** sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "market capitalization of approximately $402.4 million"
LABEL: SUPPORTED
REASON: The source data lists market_cap as $402,379,680.0, which rounds to $402.4 million; this figure also appears explicitly in the Financial Health and Recent Developments pre-written sections.

---

CLAIM: "net loss of $73.9 million"
LABEL: SUPPORTED
REASON: The source data lists net_income as -$73,949,000, which rounds to -$73.9 million; this figure is also confirmed in the Financial Health and Recent Developments pre-written sections.

---

CLAIM: "negative profit margin of -157.3%"
LABEL: SUPPORTED
REASON: Recomputed: -73,949,000 / 47,005,000 = -1.5732, i.e., -157.32%, which matches the stated -157.3% within 0.15 percentage points; also confirmed in the source data (profit_margin: -1.57322) and the Financial Health section.

---

CLAIM: "existing cash reserves are projected to sustain operations only through the third quarter of 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors sections both explicitly state "existing cash and cash equivalents are expected to fund operating expenses and capital expenditures only through the third quarter of 2027," and this is echoed in the SEC Filing Highlights pre-written section.

---

CLAIM: "lead candidate EDIT-401"
LABEL: SUPPORTED
REASON: EDIT-401 is explicitly named as the primary candidate in the RAG SEC Highlights section ("Primary Candidate (EDIT-401)") and in the SEC Filing Highlights pre-written section.

---

**OUTLOOK**

---

CLAIM: "imminent need for capital before Q3 2027"
LABEL: SUPPORTED
REASON: The source data (RAG SEC Highlights and Risk Factors) explicitly states cash is expected to fund operations only through Q3 2027, making the need for capital before that date a direct restatement of the source.

---

CLAIM: "external funding from BMS or Vertex collaborations"
LABEL: SUPPORTED
REASON: Both BMS and Vertex are explicitly named as the only significant committed potential external funding sources in the RAG SEC Highlights, RAG Risk Factors, and the SEC Filing Highlights pre-written section.

---

*No additional quantitative figures, price targets, specific thresholds, ratios, or named product milestones beyond those evaluated above appear in the Executive Summary or Outlook sections.*
